Ann Rheum Dis. 2025 Oct 28:S0003-4967(25)04428-0. doi: 10.1016/j.ard.2025.09.014. Online ahead of print.
ABSTRACT
OBJECTIVES: Thromboxane A synthase 1 (TBXAS1) deficiency results in Ghosal haematodiaphyseal dysplasia (GHDD). We identified 2 patients with TBXAS1 deficiency characterised by autoinflammation. Our objective was to explore molecular mechanisms underlying the disease and investigate the targeted therapy.
METHODS: Whole-exome sequencing and Sanger sequencing were used to identify and confirm the mutations. Quantitative reverse transcription polymerase chain reaction and Western blotting were conducted to analyse the pathway. Cytometric bead arrays, enzyme-linked immunosorbent assay, and mass spectrometry were used to detect the concentrations of cytokines, cyclic adenosine monophosphate (cAMP), and arachidonic acid metabolites. Cytometry time-of-flight and single-cell RNA sequencing were utilised to evaluate inflammatory responses and IL6 signaling activation.
RESULTS: We identified 2 patients with TBXAS1 deficiency presented with systemic inflammation, in addition to increased bone density and anaemia. TBXAS1 deficiency led to abnormal eicosanoid accumulation. The elevated prostaglandin E2 induced the expression of interleukin 6 (IL-6) via E-type prostanoid receptor 2/cAMP/cAMP response element-binding protein pathway. Patients’ peripheral blood mononuclear cells showed strong inflammatory signatures, particularly in monocytes and activation of IL6 signaling in various immune cell populations. Based on these critical findings, we treated both patients with the IL-6 inhibitor tocilizumab, resulting in complete resolution of symptoms and laboratory abnormalities, as indicated by normalised erythrocyte sedimentation rate, C-reactive protein, and eicosanoid metabolite levels, as well as improvements in bone density.
CONCLUSIONS: We provided new insights into the pathophysiology of GHDD, which highlighted a novel link between the arachidonic acid pathway and systemic autoinflammation, and proposed an effective targeted therapy for patients with GHDD or potentially other diseases associated with the dysregulation of the arachidonic acid pathway.
PMID:41162285 | DOI:10.1016/j.ard.2025.09.014
